Elagolix

Orilissa

GnRH Agonist Oral FDA/EMA Label

Half-life

6 hr

Time to Peak

1 hr

Steady State

~2 days

Dose Range

150–200 mg

Frequency

Daily

Overview

Oral non-peptide GnRH antagonist approved for endometriosis with associated pain. Unlike relugolix, dose-dependent partial suppression is possible: 150 mg once daily produces partial suppression (reduces estradiol to ~40-60 pg/mL), while 200 mg twice daily produces near-complete suppression. This dose-dependent effect is clinically useful for tailoring treatment.

Mechanism of Action

Non-peptide oral GnRH receptor antagonist. Competitive binding at pituitary GnRH receptors. Dose-dependent suppression of estradiol and progesterone.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Oral	150–200 mg	6 hr	1 hr	Daily, Twice daily

Used in Regimens

Elagolix is not currently part of any catalog regimen.

Data Sources

FDA Label Orilissa (elagolix) FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Elagolix with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.